These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 23735942)

  • 1. Biomarker discordance: why it occurs and why it is important.
    Lower EE; Khan S
    Cancer Biomark; 2012-2013; 12(6):219-30. PubMed ID: 23735942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of biomarker discordance in breast cancer from the pathologist's perspective.
    Gong Y
    Cancer Biomark; 2012-2013; 12(6):207-18. PubMed ID: 23735941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
    Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
    Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
    Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker discordance: prospective and retrospective evidence that biopsy of recurrent disease is of clinical utility.
    Moussa O; Purdie C; Vinnicombe S; Thompson AM
    Cancer Biomark; 2012-2013; 12(6):231-9. PubMed ID: 23735943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer.
    Dawood S; Gonzalez-Angulo AM
    Cancer Biomark; 2012-2013; 12(6):241-50. PubMed ID: 23735944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of HER-2/neu, ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma.
    Zheng W; Zheng J; Ma L; Meng F; Huang L; Ma D
    APMIS; 2005 Mar; 113(3):175-81. PubMed ID: 15799760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
    Stark A; Lu M; Mackowiak P; Linden M
    Breast J; 2005; 11(3):183-7. PubMed ID: 15871703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
    Arafah M
    Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
    Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
    Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?
    Prowell TM; Armstrong DK
    Semin Oncol; 2006 Dec; 33(6):681-7. PubMed ID: 17145348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
    Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
    Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.